Robyn Guymer
From Wikipedia, the free encyclopedia
Robyn Guymer | |
|---|---|
| Born | Robyn Heather Guymer |
| Alma mater | Walter & Eliza Hall Institute of Medical Research |
| Known for | Ophthalmology |
| Awards | Member, Order of Australia |
| Scientific career | |
| Fields | Ophthalmology |
| Institutions | Melbourne University |
| Thesis | A comparison of corneal, pancreas and skin allografts in mice[1] (1991) |
Robyn Guymer is an Australian ophthalmologist who was awarded an Elizabeth Blackburn Fellowship from the NHMRC, and works in ophthalmology at Melbourne University. Guymer is a senior retinal specialist within the Royal Victorian Eye and Ear Hospital, and is the deputy director, Centre for Eye Research Australia. She works in age-related macular degeneration as a clinician, academic, and researcher,[2][3][4] and has used nano-lasers to treat Age-related Macular Degeneration.[5]
Guymer was awarded her Ph.D. from the Walter and Eliza Hall Institute of Medical Research. She then trained in ophthalmology in Melbourne. Subsequently, she completed a medical retinal fellowship, in London, at the Moorfields Eye Hospital, with Professor Alan Bird.[4] She directs a team of researchers who specialise in investigating age-related macular degeneration (AMD).[4]
Guymer works in retinal disease[6] and has researched both environmental and genetic risk factors for the condition AMD. She has also investigated predictors of the responses to treatments for late AMD. Guymer is a principal investigator in a range of trials. She is on pharmaceutical advisory boards, including as the Mactel consortium, the Beckman/Ryan AMD initiative (USA) in addition to the International Classification of Atrophy (CAM) group.[7]
Guymer's career has involved investigating new strategies for the treatment of the early stages of AMD. She also researches imaging and functional biomarkers as well as surrogate endpoints with the goal of improving trials for early interventions.[2][8] Guymer has supported other Early Career Researchers in studying and treating eye conditions at the CERA.[9]
